



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

June 13, 2005

Robert W. Pollock, Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, NY 11590

Dear Mr. Pollock:

Your petition requesting the Food and Drug Administration to declare that the drug product, Ranitidine Hydrochloride Suspension (15 mg base/mL) is suitable for consideration in an abbreviated new drug application was received by this office on 06/13/2005. It was assigned docket number 2005P-0228/CP1 and it was filed on 06/13/2005. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

A handwritten signature in black ink, appearing to read "Lyle D. Jaffe", is written over the typed name.

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

2005P-0228

ACK 1